Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
Status:
Active, not recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This is phase 3b open-label, international, multicenter study to continue to monitor the
long-term safety and efficacy of burosumab in adult patients with XLH that participated in
previous clinical trials with burosumab (UX023-CL303 / UX023-CL304).